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Refractory or recurrent infections of skin, nails, and the mucous membranes are clinical signs of chronic mucocutaneous
candidiasis, frequently associated with immunological defects. Here we describe a 39-years-old female patient, with familial
CMC, that presented with an extensive infection caused by an azole-resistant Candida albicans isolate, successfully treated with
posaconazole.
1.Introduction
Chronic mucocutaneous candidiasis (CMC) is a persistent
or refractory/recurrent infection of the skin, nails, and
mucous membranes, most commonly caused by Candida
albicans, that can be related to a variety of disparate
clinical conditions, yet to be fully identiﬁed [1]. Although
diﬀerent underlying diseases predispose to CMC, they are
frequently associated with primary or secondary immun-
odeﬁciencies. Regarding secondary causes, HIV infection is
common, although other etiologies are known [1]. Among
inherited causes, sporadic, autosomal dominant (MIM
114580), and autosomal recessive (MIM 212050) forms
of CMC have been described. Moreover, similar clinical
patterns of candidiasis are shared by other primary immun-
odeﬁciencies, mainly APECED (MIM 240300) [2]a n d
autosomal-dominant hyper-IgE syndrome (MIM 147060)
[3].
The availability of azoles (e.g., clotrimazole, ketocona-
zole, itraconazole, and ﬂuconazole) represented a dramatic
improvement in the treatment of all forms of CMCs.
However, following the use of these drugs, C. albicans strains
resistant to azole antifungals have been subsequentlyisolated
[4], requiring novel therapeutic options. These include
ﬂucytosine, amphotericin B, the newest azoles and, more
recently, echinocandins.
Here we describe a case of a familial CMC, characterized
by a refractory infection caused by C. albicans resistant
to azoles, including voriconazole, successfully treated with
posaconazole that to our knowledge has not yet been
reported to treat these forms of candidiasis.
2.Case Presentation
A 39-year-old female patient was referred to our Center
in 2009, presenting a history of recurrent infections with
involvement of mucosa, nails, and skin caused by C. albicans.
At the onset, when the patient was 2years old, the fungal
infection started on the face and nails and progressively
diﬀused toothercutaneousand mucosaltissues. At3years of
age, oral thrush, labial ﬁssures, and cutaneous erythematous
desquamating patches developed and have persisted since
then. Clinical samples constantly revealed the presence of C.
albicans. The clinical diagnosis of familial CMC was posed.
The patient received courses of systemic treatment with2 Clinical and Developmental Immunology
clotrimazole. However, recurrence of candidiasis occurred
shortly after halting antifungal therapy. The patient’s family
included unaﬀected parents as well as two unaﬀected broth-
ersand twosisters, while anotherbrother,aﬀectedbyasevere
form of CMC, died when he was 6years old of fulminant
hepatitis.
At 6years of age, the patient experienced a massive
erythematous-desquamating dermatosis involving the face,
limbs, nails, and the oral, conjunctival and genital mucosa.
In addition, she developed a disﬁguring dermatophytosis,
caused by Microsporum canis, detected in the squamous
samples, restricted to face and scalp (Figure 1(a)). Treatment
with clotrimazole and griseofulvine led to a slow, albeit com-
plete, recovery, although she developed alopecia of eyelashs,
eyebrows, and scalp. Throughout her life she experienced
several recurrent infections by C. albicans,f o rw h i c hs h e
received long-term courses of diﬀerent antifungals, such as
clotrimazole, miconazole, and ketoconazole and as soon as
they became available, ﬂuconazole and itraconazole. The
therapies with azoles were overall successful to control
recurrent candidiasis. Nevertheless, since 2005 a progressive
decrease in the susceptibility of C. albicans isolates to azoles,
parallel to a worsening of her symptoms, required an
increased dosage of these drugs.
When the patient was admitted to our hospital in June
2009, she presented with an extensive candidiasis of the
mouth, hands, and feet (Figures 1(b), 1(c), and 1(d)). In
addition, she complained of dysphagia and a weight loss of
10kg in 2months. Specimens from cutaneous, pharyngeal,
and buccal swabs were positive for C. albicans, while a nasal
swab was negative. In addition to C. albicans,c u l t u r e so f
all specimens grew also Escherichia coli and Enterobacter
cloacae.AllC.albicans isolatesshowedthesamesusceptibility
proﬁlesto antifungal drugs, asdetectedwith antimycograms.
In particular, they were resistant to nystatin, ﬂuconazole,
itraconazole, voriconazole but sensitive to posaconazole,
ﬂucytosine, amphotericin B and to echinocandins. Esoph-
agogastroduodenoscopy (EGD) showed an esophageal and
duodenal candidiasis (Figure 1(e)). Cancer was excluded by
biopsy. Screening investigations including full blood count,
routine blood chemistry, C-reactive protein, liver function
tests, protein electrophoresis, levels of ferritin, urea and
electrolytes, IgA, IgG, IgE, IgM, C3, C4. and tests for thyroid,
parathyroid, adrenal, and HIV antibodies were performed.
Lymphopenia was present (800–1,200cells/mm3)w i t hl y m -
phocyte count upon admission of CD45+ 888cells/mm3
(1,600–2,400), CD3+ 772cells/mm3 (960–2500), CD4+
484cells/mm3 (540–1,400), CD8+ 238cells/mm3 (270–
930), CD19+ 40cells/mm3 (90–400), and CD16+56+
52cells/mm3(90–590). Erythrocyte sedimentation rate was
65mm/hour and all the other laboratory tests were normal,
consistent with the clinical presentation of the case. Antinu-
clearAntibodies (ANAs)were positive, butendocrinopathies
or other deﬁned autoimmune diseases were excluded. In
particular, we did not ﬁnd an association between CMC
and hypothyroidism. The thyroid function was normal, as
determined by the normal values of FT3, FT4 and TSH
(4.6pg/mL; 16.3pg/mL and 2.55µIU/mL, resp.) and nega-
tivity of antithyroid antibodies. Moreover, thyroid physical
examination andultrasonographywerenormal.Theautoim-
mune polyendocrinopathy-candidiasis-ectodermal dystro-
phy (APECED) [2], common in the Sardinian population
[5], was ruled out by genetic analysis of the AIRE gene,
that showed a wild-type sequence. Hyper-IgE syndrome
w a se x c l u d e db yc l i n i c a lf e a t u r e s[ 3] and IgE levels were
normal (4.63kU/L).HIV infection was ruled out by negative
serological and viral RNA-based tests. Diabetes mellitus,
neoplasias, immunosuppressive treatments, and other clin-
ical conditions commonly associated with Candida infection
were also ruled out.
The diagnosis of familial CMC was conﬁrmed and a
treatment with amphotericin-B (50mg/day IV) for 2weeks
was promptly started for the treatment of severe resistant
skin, mouth, and esophageal candidiasis, resulting in an
improvement of dysphagia. Orally administered posacona-
zole (400mg twice per day) replaced amphotericin-B, result-
ing in a signiﬁcant regression of the dysphagia as well
as a clear improvement of the cutaneous candidiasis after
2weeks of treatment. Onychomycosis regressed partially and
moreslowlyduringthefollowingmonths(Figure 1(f)).After
2months, the dosage of oral posaconazole was reduced to
200mg once a day, without a relapse of clinical symptoms.
The therapy was temporarily discontinued after
3months. About 2weeks later, a relapse of candidiasis was
observed, although it was limited to the oral mucosa, with
no involvement of other sites. Posaconazole was then started
again at a dosage of 200mg, three times per day for a month
with a 15-day discontinuation. As maintenance therapy, this
regimen is being repeated cyclically with no observable side
eﬀects.
3.Discussion
Although CMCs can arise from a variety of clinical condi-
tions, they may disclose rare primary immunodeﬁciencies,
reﬂectingdefectsintheﬁrstlineofhostdefenceagainstfungi.
Interestingly, Glocker et al. [6]a n dF e w e r d ae ta l .[ 7]
recently reported the ﬁrst monogenetic defects in humans,
who presented with the clinical features of CMC and other
mycoses, caused by mutations in the genes encoding CARD9
(MIM 607212) and Dectin-1 (MIM 613108). These defects
are linkedto therole thatthese proteinsplay intheactivation
of the multifaceted Th17 lymphocytes and their production
of interleukins (e.g., IL-17 and IL-22) for epithelial host
defense against fungal infection. Animal models suggested
that, a multipart pathway, starting from the yeast transmem-
brane pattern recognition receptor Dectin-1 on epithelial
cells and phagocytes, leads to the activation of the CARD9
signaling complex that produces cytokines that initiate
diﬀerentiation of CD4+ T lymphocytes toward the Th17
phenotype, crucial for the adaptive antifungal immunity
[8]. In addition, the discovery in humans of autoantibodies
against IL-17 and IL-22, as recently observed in APECED
[9, 10] further supports the role of Th17 in host defense
against Candida. Finally, new evidencesupporting the role of
IL-22 in protection from candidiasis has been reported [11,
12]. Therefore, impairment of the Th17 lymphocytes and/orClinical and Developmental Immunology 3
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Figure 1: (a) Extensive dermatophytosis, caused by M. canis at 6years of age. (b–e) Clinical presentation of C. albicans infection at the time
of admission: (b) whitish and yellowish plaques on the tongue and perleche, secondary to candidal infection; (c) skin and nail of the right
thumb, (d) skin and nails of the feet; (e) endoscopy showing severe esophagitis. (f) Hands and feet after 8months of treatment with oral
posaconazole,showing a complete regression of skin and nails candidiasis.
their cytokines appears to be the common denominator of
genetically heterogeneous but clinically related disorders.
CMCs are characterized by persistent refractory/recur-
rent infections, commonly caused by C. albicans,a n d
occasionally complicated by dermatophytosis [1], and there-
fore require long-term and extensive antifungal treatment.
Until the late 1980s, patients with chronic candidiasis were
typically treated only when symptomatic. From the late
1980s, the availability of new azoles (e.g., clotrimazole,
ketoconazole, itraconazole and ﬂuconazole) represented a
dramaticimprovementinthemanagement, prophylaxis,and
treatment of these forms of CMC. However, following the
use of these drugs, a decrease in the susceptibility of the C.
albicans strains to azole antifungals became common and, in
the treated patients, the therapeutic response started failing
with the consequent development of refractory candidal
infections [4].Othertherapeuticoptionsincludeﬂucytosine,
amphotericin B, and the newest azoles, such as voricona-
zole and posaconazole, and more recently echinocandins.
Diﬀerent studies have reported successful treatments of
CMC caused by azole-resistant isolates of Candida spp.,
with systemic amphotericin B [13–15], voriconazole [16], or
echinocandins [17, 18].
In the case of our patient, besides nails, skin, and
oral mucosa, an extensive esophageal and duodenal azole-
resistant C. albicans infection was also present. While topical
therapy is ineﬀective, oral or intravenous azoles represents
ﬁrst-line treatments of these forms [19]. Nevertheless, C.
albicans resistant to azoles, including voriconazole, leaves
clinicians with few therapeutic options, further limited by
toxicityand route ofadministration. Althoughamphotericin
B or echinocandins are primarily recommended in the
treatment of esophageal infection caused by azole-refractory
Candida spp.[ 19], diﬃculties regarding the intravenous
route of administration and/or toxicity, particularly for
prolonged use, may be problematic. Among the possible
choices, posaconazole has the advantage of being both safe
in long-term use and orally administrable [19, 20]. For this
reason, we chose to treat our patient with oral posaconazole,
even though amphotericin B was promptly administered,
giventhepatient’sconditionsandthetimerequiredtoobtain
posaconazole. The treatment was very well tolerated and4 Clinical and Developmental Immunology
brought complete control of the C. albicans in all sites
of infection. An intermittent posaconazole administration
scheme is currently undergoing, aiming to reduce the relapse
rate and, possibly, the risk of resistance.
4.Conclusions
Although in the case of our patient a speciﬁc genetic
explanation for her hereditary primary immunodeﬁciency
cannot yet be oﬀered, posaconazole treatment of the chronic
infection sustained by azole-resistant C. albicans was con-
ﬁrmed tobeappropriate,givenboththepatient’sclinicaland
microbiological history.
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